San Francisco Bay Area biotech stories.
Tuesday, August 7, 2012
Stanford researchers launch brain cancer study using Nektar drug
A team of
researchers will test a
Nektar Therapeutics Inc.
drug in a Phase II trial aimed at a common and aggressive form of brain cancer, the company said Tuesday.
, a Stanford professor of neurology and neurosurgery, and co-investigators Dr.
will test Nektar's etirinotecan pegol in patients with high-grade glioma whose cancer is resistant to
Inc.'s Avastin, or bevacizumab.
Share to Twitter
Share to Facebook
Share to Pinterest
Post a Comment
Post Comments (Atom)